For a newly diagnosed patient starting Adderall (mixed amphetamine salts), should treatment begin with an immediate‑release (IR) formulation or an extended‑release (XR) formulation?

Starting Adderall in Newly Diagnosed ADHD: Extended-Release vs. Immediate-Release

For newly diagnosed patients starting Adderall, begin with extended-release (XR) formulation rather than immediate-release (IR), as XR provides superior 12-hour symptom coverage with once-daily dosing, reduces the need for supplemental IR dosing, and improves practical adherence while maintaining equivalent efficacy and safety. 1, 2

Rationale for Extended-Release as First-Line

Duration of Coverage and Practical Advantages

• Extended-release mixed amphetamine salts (MAS XR) provides 12 hours of symptom control with a single morning dose, beginning action within 1.5 hours and maintaining therapeutic levels throughout the day 1

• MAS XR significantly reduces the need for afternoon IR supplementation compared to other extended-release formulations, simplifying the treatment regimen and improving real-world outcomes 2

• The bioavailability of MAS XR 20 mg is comparable to MAS IR 10 mg twice daily, but eliminates the compliance challenges of multiple daily doses 1

Adherence Considerations

• While pill counts and self-reports show similar adherence between IR and XR formulations, objective electronic monitoring (MEMS) demonstrates significantly better adherence with XR, which is clinically relevant for newly diagnosed patients establishing treatment routines 3

• For adolescents specifically, longer-acting formulations provide critical symptom control during driving hours, reducing crash risk and motor vehicle violations—a major safety concern in this population 4

Efficacy and Safety Profile

• Both MAS IR and MAS XR demonstrate equivalent efficacy in reducing ADHD symptoms across all age groups (children, adolescents, and adults), with no significant differences in ADHD Rating Scale scores or Clinical Global Impressions 3, 5, 1

• MAS XR has been established as safe and generally well-tolerated in short- and long-term studies across all age populations, including adults with controlled hypertension 5

• The extended-release formulation minimizes peak-to-trough plasma concentration fluctuations, potentially reducing side effect burden compared to multiple IR doses 6

Special Populations Requiring Modified Approach

Adolescents with Substance Use Risk

• Before initiating any amphetamine formulation in adolescents, assess for active substance use; if present, refer to subspecialist for guidance 4

• Monitor prescription refill patterns for signs of diversion or misuse, as this is a particular concern in adolescent populations 4

• Consider that XR formulations have lower abuse potential than IR due to their pharmacokinetic profile, though both require monitoring 4

Preschool-Age Children (Under 6 Years)

• Amphetamine formulations are not first-line for preschool-aged children; methylphenidate has more evidence in this age group, and even then only for moderate-to-severe dysfunction unresponsive to behavioral interventions 4

• If medication is necessary in very young children, start with the lowest possible dose and increase in smaller increments due to slower metabolism 4

Dosing Strategy for Treatment Initiation

• Start with lower doses of MAS XR and titrate upward based on response and tolerability, following the same principle as IR formulations but with the convenience of once-daily administration 1

• The standard starting approach mirrors the 3:1 ratio of dextroamphetamine to levoamphetamine found in IR formulations, maintaining consistent pharmacology 1

• If patients demonstrate inadequate late-day coverage despite optimal XR dosing, consider supplemental low-dose IR in the afternoon rather than switching entirely to IR regimen 6, 2

Common Pitfalls to Avoid

• Do not assume IR allows for "better titration"—XR formulations can be titrated equally well and provide more consistent plasma levels throughout the day 6, 1

• Avoid starting with IR simply because it's "traditional"—the evidence supports XR as providing equivalent efficacy with practical advantages in real-world adherence 3, 2

• Do not overlook cardiovascular screening before initiating any amphetamine formulation, regardless of whether IR or XR is chosen 5